Brendan M. Muoio, PharmD

  • 2Articles
  • 8.4KReads1
  • 2017–2018Active
  • 9Collaborators
  • 44Citations2

About

Brendan M. Muoio, PharmD, has contributed to the fields of neurology and psychopharmacology through publications on regulatory perspectives regarding antipsychotic medications. His work includes analysis of the FDA's approval processes for aripiprazole tablets with sensor technology and the antipsychotic pimavanserin. Muoio's articles were published between 2017 and 2018 in Psychiatrist.com, the Journal of Clinical Psychiatry and The Primary Care Companion for CNS Disorders.

Publications

JCP
Perspective

FDA's Approval of Aripiprazole Tablets With Sensor

May 29, 2018

The recent FDA approval of aripiprazole tablets with sensor met with a myriad of reactions, including concerns about patient privacy and autonomy. In this Perspectives article, authors from the...
, , , et al
JCP
Review Article

FDA Perspective on Pimavanserin

June 28, 2017

In 2016, pimavanserin became the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. This article describes the regulatory and clinical issues important to the FDA's...
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe